Antion Biosciences Present New Data at miCARTM T cells and Multiplex genetic engineering Technology at American Society for Gene and Cell Therapy (ASGCT) Annual meeting
- New miCAR™ gene constructs demonstrate high gene silencing efficiency with simultaneous expression of CAR to create allogeneic CAR T–cells
- Anti-CD19 miCAR™ T cells show efficient deactivation of two key inhibitor receivers necessary for effective allogeneic B cell lymphoma therapy
Geneva, Switzerland, 12 May 2021 – Antion Biosciences (“ Antion ” or “ the Company ”), a Swiss cellular and genetic engineering company developing highly innovative allogeneic therapies to treat diseases with significant unmet medical need, today announced Additional positive data on its developmental allogeneic chimeric antigen receptor T- cell therapies (CAR-T cells) created using its new miCAR ™ (“miCAR”) platform, at the annual meeting of the American Society of Gene & Cell Therapy (ASGCT), which will take place May 11-14.
Antion presented data from two independent preclinical studies in two posters that provide evidence for the use of their proprietary miCAR construct in the development of allogeneic therapies based on next-generation CAR-T cells. Together, these two posters demonstrate Antion’s multiplex cell engineering capabilities, including the expression of a CAR with the simultaneous modulated silencing of three relevant genes in the creation of a novel optimized allogeneic therapy (see below for more details).
Dr. Sven Kili, CEO of Antion Biosciences commented: “I am delighted to share this data which demonstrates the proof of principle of our new bimodal miCAR gene construct. The next generation CD19 allogeneic CAR-T cells that we developed using our novel miCAR gene construct, demonstrated simultaneous CAR expression and efficient gene silencing of clinically relevant receptors. Our miCAR construct also offers efficient one-step multiplex cell engineering, which will be essential in overcoming the challenges faced by existing gene editing approaches. Through these proof-of-principle studies, Antion’s miCAR T cells demonstrate their potential as a promising immunotherapeutic solution for a number of disease indications. In addition, we believe that the miCAR platform offers a simpler, more efficient and more effective route to allogeneic therapies. “
Poster 1: Abstract #642 – Chimeric antigen receptor anti-CD19 T cell development with immune checkpoint deactivation
Anti-CD19 CAR-T cells were designed with simultaneous silencing of PD1 and TIM3, inhibitory receptors known to be relevant in the context of relapsed / refractory diffuse B-cell lymphoma. These miCAR-T cells were transduced to express CAR with simultaneous silencing of PD1 and TIM3. The data demonstrate the efficient one-step creation of next-generation anti-CD19 CAR-T cells via novel Antion miCAR gene constructs to achieve simultaneous CAR expression and gene silencing of relevant inhibitory receptors. This laid the foundation for the development of a fully allogeneic CAR-T cell used in the second study.
Poster 2: Abstract # 391 – A new bimodal gene construct for multiplex cell engineering and the development of allogeneic T cells of the chimeric antigen receptor
The second study was conducted to demonstrate the potential of Antion’s anti-CD19 CAR-T cells as an effective allogeneic treatment option. In this study, miCAR constucts were delivered to primary T cells to assess gene silencing while maintaining killing efficiency. The data showed complete gene silencing of the T cell receptor (TCR) and predicted 75-95% silencing against inhibitory PD1 and HLA class I receptor molecules, while maintaining efficient recognition and destruction capabilities. The variable silence of these molecules prevents a host immune response which is essential for effective and safe allogeneic therapies. These data therefore demonstrate Antion’s ability to “ tune ” its silencing constructs and further demonstrate the flexibility of the miCAR platform to create persistent allogeneic immune effector cells with high killing efficiency.
Both digital poster presentations are now available for viewing by ASGCT attendees on the ASGCT website: https://annualmeeting.asgct.org/. Posters will also be available after the event on the Antion website: https://antion.ch/#/media.
– Ends –
For more information, please contact:
|Antion Biosciences||Strategic communications of the Consilium|
|Dr Sven Kili, Managing Director
Email: [email protected]
|Matthew Neal / Chris Gardner / Ashley Tapp
Telephone: +44 (0) 20 3709 5700
Email: [email protected]
About Antion Biosciences
Antion Biosciences SA is a Swiss cellular and genetic engineering company that develops highly innovative allogeneic therapies to treat diseases with significant unmet medical needs through revolutionary cell engineering. Antion’s proprietary Minigene Therapeutics (TMG) and miCAR ™ technologies enable efficient and simultaneous multigene silencing and one-step addition of genes enabling the creation of multimodal therapies that have the ability to dramatically improve safety and performance. clinical efficacy. These technologies are developed using a unique Smart Data approach for construction design and optimization, ensuring maximum efficiency. Antion’s pipeline is focused on curing difficult indications of cancer, HIV and sensory disorders through simple, easy-to-administer cell therapies. Antion has a world-class management and advisory team and was founded in 2016 by internationally renowned scientists and clinicians.
For more information, please visit: https://antion.ch/#/